We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
India’s Bharat Biotech plans to produce 700 million doses of its newly approved vaccine this year, the company’s managing director Krishna Ella said Monday. Read More
Researchers at China’s Shenzhen Institutes of Advanced Technology have found that pralatrexate, a chemotherapy drug used to treat lymphoma, may hold potential as a COVID-19 treatment and that it outperforms remdesivir in inhibiting the virus. Read More
Late Monday, the FDA’s two top officials hinted that the agency is unlikely to adopt the Trump administration’s idea of giving two half doses of Moderna’s COVID-19 vaccine to patients aged 18 to 55 in order to double the number of vaccinations being administered, as suggested by Operation Warp Speed’s chief adviser Moncef Slaoui. Read More
Swedish contract manufacturer Recipharm has entered into an agreement to manufacture Moderna’s COVID-19 vaccine, mRNA-1273, for markets outside of the U.S. at its facility in France. Read More
Despite the serious challenges the FDA faced in responding to the COVID-19 pandemic in 2020, the agency ended the year approving more novel drugs than in four of the five previous years. Read More
Regeneron has released positive initial results from an ongoing phase 1/2/3 study evaluating its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients who require low-flow oxygen. Read More
China announced that it has granted conditional authorization for one of Sinopharm’s inactivated COVID-19 vaccines, a shot that the state-owned pharma company claimed is 79.3 percent effective according to an interim analysis of its phase 3 trial. Questions remain, however, due to a lack of details from the company. Read More
The World Health Organization (WHO) has granted the Pfizer/BioNTech COVID-19 vaccine an Emergency Use Listing — the first such listing by the standard-setting body since the pandemic began. Read More